Welcome to our dedicated page for ICON news (Ticker: ICLR), a resource for investors and traders seeking the latest updates and insights on ICON stock.
ICON plc reports developments for a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology companies. Its news commonly covers operating and financial results, clinical trial management activity, net business wins, revenue guidance, and service areas such as patient recruitment, data analytics, laboratory services and regulatory consulting.
Company updates also address partnerships that connect clinical trial technology with research-site systems, expansion of the Accellacare Site Network in therapeutic areas including oncology, and governance or accounting-control matters tied to revenue recognition and financial reporting.
ICON plc (NASDAQ: ICLR), a leading global provider of outsourced drug and device development, announced key presentations at upcoming healthcare conferences. Mr. Brendan Brennan, CFO, will present at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 08:00 AM ET. Dr. Steve Cutler, CEO, will present at the William Blair 41st Growth Stock Conference on June 2, 2021, at 11:40 AM ET. Live webcasts will be available on their Investor section. The company continues its strategic growth and service expansion in clinical development.
ICON plc (NASDAQ: ICLR), a leading global provider of outsourced drug and device development services, announced that CFO Brendan Brennan will present at two upcoming virtual healthcare conferences. The first presentation is scheduled for May 12, 2021, at the BofA Securities 2021 Virtual Healthcare Conference, followed by the UBS Virtual Global Healthcare Conference on May 24, 2021. For updates on these events, please check the Investor section of ICON's website. The company, headquartered in Dublin, employs approximately 16,070 staff across 89 locations globally.
ICON (NASDAQ: ICLR) reported strong financial results for Q1 2021 with revenue reaching $858 million, a 20% year-on-year increase. The company achieved record net business wins of $1.1 billion, up 27% year-on-year, and grew its backlog to $10 billion. Adjusted earnings per share rose 21% to $2.06. ICON has raised its full-year revenue guidance to $3.4 - $3.5 billion, reflecting a 21.6% - 25.1% increase year-on-year. The planned acquisition of PRA is set to close in July, enhancing ICON's market position.
ICON plc (NASDAQ: ICLR) recently announced that CFO Brendan Brennan will present at two significant events: the Barclays Global Healthcare Conference on March 10, 2021, at 08:00 am ET, and at the KeyBanc Capital Markets' Life Sciences & MedTech Investor Forum on March 24, 2021, at 11:30 am ET. The presentations will be accessible via live webcasts, with details available on the Investor section of ICON's website under 'Events.' ICON is a leading provider of outsourced drug and device development services, currently employing approximately 15,730 staff globally.
ICON plc (NASDAQ: ICLR) reported strong Q4 2020 results, with record net business wins of $1,080 million and a book-to-bill ratio of 1.42, increasing backlog to over $9.7 billion (up 13% YoY). Revenue grew by 5% to $760 million, and EPS rose to $1.90 (up 4%). For 2021, revenue guidance is set at $3,200 - $3,300 million, reflecting a 14% - 18% increase, with EPS guidance of $8.10 - $8.50 (24% - 30% increase). Despite the pandemic's challenges, ICON remains focused on safety and continues to manage over 120 COVID-19 trials. Full-year revenue declined slightly by 0.3% to $2,797 million.
ICON plc (NASDAQ: ICLR) has announced a definitive agreement to acquire PRA Health Sciences (NASDAQ: PRAH) for approximately $12 billion. The acquisition will involve $80 in cash and 0.4125 shares of ICON stock per PRA share, representing a 30% premium from PRA's closing price on February 23, 2021. The merger aims to enhance clinical trial execution and increase efficiency, delivering an estimated $150 million in cost synergies. The deal is expected to close in Q3 2021, subject to regulatory approvals.
Cytocom has submitted an IND application to the FDA for a Phase 2 clinical trial of CYTO-205, aimed at evaluating its efficacy against COVID-19. Preclinical studies indicate CYTO-205 may inhibit coronavirus strain 229E replication in lung cells. The trial, commencing in Q2 2021, targets high-risk adults with mild COVID-19 infection. Additionally, Cytocom partnered with ICON plc to manage the Phase 3 trial for CYTO-201, its lead candidate for Crohn's disease. The company emphasizes the need for effective COVID-19 therapies despite vaccine availability.
ICON plc (NASDAQ: ICLR) has launched two new digital solutions, FIRECREST Safety Letters and FIRECREST Site Question Management, enhancing clinical research efficiency. The integrated FIRECREST suite allows for electronic acknowledgment of safety letters with compliance tracking. It simplifies safety letter management, enabling quick sponsor reconciliation and ensuring regulatory compliance. The Site Question Management solution streamlines medical query handling, improving response times. With 540,000 users across 233 indications, these innovations support top pharmaceutical companies in navigating complex safety reporting.
ICON plc (NASDAQ: ICLR), a global provider of outsourced drug and device development, announced that Dr. Steve Cutler, CEO, and Mr. Brendan Brennan, CFO, will present at the 39th Annual JP Morgan Healthcare Conference on January 12, 2021, at 7:30 AM ET. The presentation will cover strategic developments in drug and device commercialization. Interested parties can access updates and links to live webcasts on the Investor Relations section of their website under 'Events'. As of September 30, 2020, ICON employed approximately 15,250 people across 94 locations worldwide.
ICON plc (NASDAQ: ICLR) announced the release of its inaugural Environmental, Social and Governance (ESG) Report, showcasing its ESG policies and commitments, as well as progress made in 2019. This report is part of ICON's strategy to enhance transparency and accountability in its operations. The ESG report is accessible here. As of September 30, 2020, ICON employed approximately 15,250 individuals across 94 locations in 40 countries, solidifying its global presence in pharmaceutical and biotechnology sectors.